PRESS

San Francisco, March 7, 2025 - Recardio Inc., a late clinical-stage life science company developing therapies for cardiovascular and other diseases, today announced that the company has signed a letter of intent for a planned license agreement with the public Swedish biotech company, Kancera AB (Kancera). Kancera and Recardio have agreed to evaluate combining both companies’ assets and resources through a transaction in which Recardio would in-license drug candidates, KAND567

San Francisco, January 9, 2025 - Recardio Inc., a late-stage clinical-stage life science company focusing on therapies for cardiovascular...

San Francisco, December 4, 2024 - Recardio Inc., a late stage clinical stage life science company developing therapies for cardiovascular and other diseases, announced the filing of a new international patent application with the potential of significantly improving administration of the company’s lead drug candidate Dutogliptin. Recardio filed a new international patent application for its novel formulation process Recardio has filed a new international PCT application, publ